Status
Enrolling by invitation
Phase
Not applicable
Enrollment
100
Locations
1
Results
Not posted
Publications
0
Study summary
The purpose of the study is to determine whether patients taking GLP-1 RAs have increased residual (left behind), gastric (stomach), contents due to delayed gastric emptying when following standard preoperative fasting guidelines.
Interventions
DRUG
GLP-1 RAs: Glucagon like peptide-1 receptor agonists, this includes patients who are on Liraglutide, Semaglutide, Dulaglutide and Tirzepatide.Tirzepatide which is a combined GLP-1 RA/glucose-dependent insulinotropic polypeptide (GIP) agonist is included as a part of GLP-1 RAs.
DIAGNOSTIC_TEST
A gastric ultrasound following a standard NPO period to determine gastric contents and risk of aspiration during surgery.
Timeline
First posted
Sep 3, 2024
Study start
Jul 8, 2024
Primary completion
Jul 2026
Study completion
Jul 2026
Results posted
Not reported
Registry updated
Nov 7, 2024
Outcomes
Aspiration Risk determined by POGUS
Time frame · Two years
Difference between control group and GLP-1 group. Measured by Gastric contents during Point of Care Gastric Ultrasound.
Not reported in the indexed record.
Eligibility
Inclusion Criteria: * Body Mass Index over 35 * Type 2 Diabetes * Currently taking GLP01 RA agonist (for GLP 1 group) * Not taking GLP-1 RA agonist (for control group) Exclusion Criteria: * Diagnosis of gastroparesis * patient refusal to participate * Previous gastric bypass or any other gastric surgery * Currently on peritoneal dialysis * Abdominal pathology * Gastro-intestinal obstruction * Pregnancy
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
Cincinnati Children's Hospital
Cincinnati, Ohio, United States
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
4Moving Biotech · Knee Osteoarthritis · Synovitis of Knee
Phase 2
Active, not recruiting
129
2026-07
Ohio State University · Obesity & Overweight · Diabetes (DM)
Not applicable
Recruiting
300
2026-07
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Type 2 Diabetes Mellitus · Mild Cognitive Impairment
Not applicable
Completed
396
2026-07
Phase 1
Recruiting
71
2026-07
Eli Lilly · Type 2 Diabetes
Phase 3
Recruiting
55
2026-07
Eli Lilly · Diabetes Mellitus, Type 2
Phase 3
Not yet recruiting
170
2026-07
Brigham and Women's Hospital · Type 2 Diabetes
Not applicable
Completed
300,000
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.